Microtubule Active Agents: Beyond the Taxane Frontier
- 14 November 2008
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (22), 7167-7172
- https://doi.org/10.1158/1078-0432.ccr-08-0169
Abstract
Microtubules are essential to cell transport, signaling, and mitosis. An increasing range of anticancer drugs interferes with the normal formation and function of microtubules. Vinca alkaloids act as microtubule destabilizers and the taxanes act as microtubule stabilizers. Taxanes are widely used cytotoxic agents that are active in a range of solid tumor malignancies and are routinely used in a variety of settings. Significant limitations with the taxanes exist, including acquired and intrinsic tumor resistance through the expression of multidrug resistance proteins such as P-glycoprotein, risk of hypersensitivity reactions, dose-limiting hematopoietic toxicity, and cumulative neurotoxicity. Hence, there is a need to develop novel agents that act on the microtubules. Epothilones are macrolide antibiotics that bind near the taxane-binding site on microtubules and have been extensively studied in recent and ongoing clinical trials. A variety of other agents that act on the microtubules at different sites with a variety of structures are at varying stages of development.Keywords
This publication has 59 references indexed in Scilit:
- Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly scheduleAnnals of Oncology, 2007
- Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline ChemotherapyJournal of Clinical Oncology, 2007
- Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxelInvestigational New Drugs, 2007
- Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patientsCancer, 2007
- Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactionsInvestigational New Drugs, 2007
- Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumorsCancer Chemotherapy and Pharmacology, 2007
- Total Synthesis and Antitumor Activity of ZK‐EPO: The First Fully Synthetic Epothilone in Clinical DevelopmentAngewandte Chemie International Edition, 2006
- A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group studyInvestigational New Drugs, 2006
- Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II studyBritish Journal of Cancer, 2006
- Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five DaysJournal of Clinical Oncology, 2003